Pfizer Acquires Seagen for $43 Billion
December 14, 2023
Pfizer completed its acquisition of Seagen, acquiring all outstanding common stock of Seagen for $229 per share in cash, valuing the enterprise at approximately $43 billion. The combination is intended to strengthen Pfizer’s oncology portfolio by adding Seagen’s proprietary antibody-drug conjugate (ADC) technology and in-line medicines.
- Buyers
- Pfizer Inc.
- Targets
- Seagen Inc.
- Industry
- Biotechnology
- Location
- Washington, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.